Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 2/2000

Open Access 01-08-2000 | Commentary

Debate: Are surrogate end-point studies worth the effort?

Authors: Jonathan Valabhji, Dr Robert S Elkeles

Published in: Trials | Issue 2/2000

Login to get access

Abstract

Surrogate end-points of cardiovascular disease can provide useful information in cross-sectional, prospective and interventional studies. They provide information on association with risk factors, natural history and factors associated with disease progression. Because every participant can reach an end-point, sufficient power can be attained with much smaller numbers of subjects in surrogate end-point studies than in studies that use clinical endpoints, so that the costs are likely to be substantially less. Measures of carotid intima-media thickness (IMT) by B-mode ultrasonography and of coronary calcification by electron beam computed tomography (EBCT) appear to be the most promising surrogate end-points.
Literature
1.
Knutsen R, Knutsen SF, Curb JD, Reed DM, Kautz JA, Yano K: The predictive value of resting electrocardiograms for 12-year incidence of coronary heart disease in the Honolulu Heart Program. J Clin Epidemiol. 1988, 41: 293-302.CrossRefPubMed
2.
Jarrett RJ, McCartney P, Keen H: The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia. 1982, 22: 79-84.PubMed
3.
Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster : Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988, 12: 56-62.CrossRefPubMed
4.
Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990, 323: 1289-1298.CrossRefPubMed
5.
Wada T, Kodaira K, Fujishiro K, Maie K, Tsukiyama E, Fukumoto T, Uchida T, Yamazaki S: Correlation of ultrasound-measured common carotid artery stiffness with pathological findings. Arterioscler Thromb . 1994, 14: 479-482.CrossRefPubMed
6.
Hirai T, Sasayama S, Kawasaki T, Yagi S: Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. Circulation. 1989, 80: 78-86.CrossRefPubMed
7.
Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992, 340: 1111-1115. 10.1016/0140-6736(92)93147-F.CrossRefPubMed
8.
Goodfellow J, Ramsey MW, Luddington LA, Jones CJ, Coates PA, Dunstan F, Lewis MJ, Owens DR, Henderson AH: Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. Br Med J. 1996, 312: 744-745.CrossRef
9.
Grobbee DE, Bots ML: Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med. 1994, 236: 567-573.CrossRefPubMed
10.
Salonen JT, Salonen R: Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation . 1993, 87 (Suppl 3): 1156-1165.
11.
O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999, 340: 14-22. 10.1056/NEJM199901073400103.CrossRefPubMed
12.
Adams MR, Nakagomi A, Keech A, Robinson J, McCredie R, Bailey BP, Freedman SB, Celermajer DS: Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation. 1995, 92: 2127-2134.CrossRefPubMed
13.
Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994, 89: 2462-2478.CrossRefPubMed
14.
Heickendorff L, Ledet T, Rasmussen LM: Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque. Diabetologia. 1994, 37: 286-292. 10.1007/s001250050107.CrossRefPubMed
15.
Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998, 21: 641-648.CrossRefPubMed
16.
Belcaro G, Barsotti A, Nicolaides AN: `Ultrasonic biopsy': a non-invasive screening technique to evaluate the cardiovascular risk and to follow up the progression and the regression of arteriosclerosis. Vasa. 1991, 20: 40-50.PubMed
17.
Blankenhorn D, Selzer R, Crawford D, Barth JD, Liu C, Mack WJ, Alaupovic P: Beneficial effects of Colestipol-Niacin therapy on the common carotid artery. Circulation. 1993, 88: 20-28.CrossRefPubMed
18.
Furberg CD, Byington RP, Crouse JR, Espeland MA: Pravastatin, lipids, and major coronary events. Am J Cardiol. 1994, 73: 1133-1134.CrossRefPubMed
19.
Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994, 90: 1679-1687.CrossRefPubMed
20.
Salonen R, Nysyssonen K, Porkkala E, Rummukainen J, Belder R, Park J-S, Salonen JT: Kuopio Atherosclerosis Prevention Study (KAPS). Circulation. 1995, 92: 1758-1764.CrossRefPubMed
21.
Agatston A, Janowitz W, Hildner F, Zusmer N, Viamonte MJ, Detrano R: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990, 15: 827-832.CrossRefPubMed
22.
Detrano R, Hsiai T, Wang S, Puentes G, Fallavollita J, Shields P, Stanford W, Wolfkiel C, Georgiou D, Budoff M, Reed J: Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. J Am Coll Cardiol. 1996, 27: 285-290. 10.1016/0735-1097(95)00460-2.CrossRefPubMed
23.
Secci A, Wong N, Tang W, Wang S, Doherty T, Detrano R: Electron beam computed tomographic coronary calcium as a predictor of coronary events: comparison of two protocols. Circulation. 1997, 96: 1122-1129.CrossRefPubMed
24.
Arad Y, Spadaro L, Goodman K, Lledo-Perez A, Sherman S, Lerner G, Guerci AD: Predictive value of electron beam computed tomography of the coronary arteries. 19 month follow-up of 1173 asymptomatic subjects. Circulation. 1996, 93: 1951-1953.CrossRefPubMed
25.
Detrano RC, Wong ND, Doherty TM, Shavelle RM, Tang W, Ginzton LE, Budoff MJ, Narahara KA: Coronary calcium does not accurately predict near-term future coronary events in high-risk adults. Circulation . 1999, 99: 2633-2638.CrossRefPubMed
26.
Thompson GR, Elkeles RS, Gibson K, Rubens M, Underwood R: Coronary calcification score and predicted risk of coronary heart disease. Atherosclerosis. 2000, 151: 4-10.1016/S0021-9150(00)80018-0.CrossRef
27.
Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998, 339: 1972-1978. 10.1056/NEJM199812313392703.CrossRefPubMed
Metadata
Title
Debate: Are surrogate end-point studies worth the effort?
Authors
Jonathan Valabhji
Dr Robert S Elkeles
Publication date
01-08-2000
Publisher
BioMed Central
Published in
Trials / Issue 2/2000
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/cvm-1-2-072

Other articles of this Issue 2/2000

Trials 2/2000 Go to the issue

Commentary

Clinical applicability of molecular biology: the case of the long QT syndrome

Review

Low-molecular-weight heparins in the treatment of venous thromboembolism

Commentary

Debate: The slippery slope of surrogate outcomes

Editorial

An essential guide to the literature

Review

Gene therapy for lipid disorders

Commentary

Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?